Improved Treatment Outcomes by Using Patient Specific Drug Combinations in Mammalian Target of Rapamycin Activated Advanced Metastatic Cancers

Background: Activation of the mTOR signaling pathway is ubiquitous in cancers and a favourable therapeutic target. However, presently approved mTOR inhibitor monotherapies have modest benefits in labeled indications while poor outcomes have been reported for mTOR inhibitor monotherapy when administe...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Front Pharmacol
Prif Awduron: Crook, Timothy, Patil, Darshana, Gaya, Andrew, Plowman, Nicholas, Limaye, Sewanti, Ranade, Anantbhushan, Bhatt, Amit, Page, Raymond, Akolkar, Dadasaheb
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Frontiers Media S.A. 2021
Pynciau:
Pharmacology
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8085687/
https://ncbi.nlm.nih.gov/pubmed/33935721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2021.631135
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg